文献速递血管炎

复方磺胺甲噁唑预防可减少抗中性粒细胞胞质抗体相关性血管炎患者接受利妥昔单抗后发生的严重/危及生命的感染

Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
PubMed 文献 · Ann Rheum Dis · 2018-06-27

该研究纳入192例接受利妥昔单抗治疗的抗中性粒细胞胞质抗体相关性血管炎(AAV)患者,分析严重感染的危险因素。49例(25.52%)共发生95次严重感染,事件率为26.06/100人年。预防性使用复方磺胺甲噁唑与严重感染频率降低相关(HR 0.30,95%CI 0.13至0.69),而高龄、支气管内受累、慢性阻塞性肺疾病和既往阿仑单抗使用增加风险。

要点

  • 接受利妥昔单抗的AAV患者中约四分之一发生严重感染,事件率26.06/100人年。
  • 预防性使用复方磺胺甲噁唑与严重感染风险降低相关(HR 0.30,95%CI 0.13至0.69)。
  • 支气管扩张和支气管内受累是严重呼吸道感染的危险因素。

核心结论

  • 接受利妥昔单抗治疗的AAV患者中约四分之一发生严重感染。
  • 复方磺胺甲噁唑预防可降低严重感染风险,而支气管扩张和支气管内受累尤其是严重呼吸道感染的危险因素。

研究设计与样本

  • 研究纳入192例接受利妥昔单抗治疗的AAV患者,采用单因素和多因素分析识别严重感染的危险因素。
  • 严重感染按常见不良事件评价标准V.4.0定义为≥3级。

主要发现

  • 49例(25.52%)患者共记录95次严重感染,事件率为26.06/100人年。
  • 预防性使用复方磺胺甲噁唑与严重感染频率降低相关(HR 0.30,95%CI 0.13至0.69)。
  • 高龄(HR 1.03,95%CI 1.01至1.05)、支气管内受累(HR 2.21,95%CI 1.14至4.26)、慢性阻塞性肺疾病(HR 6.30,95%CI 1.08至36.75)和既往阿仑单抗使用(HR 3.97,95%CI 1.50至10.54)与严重感染风险升高相关。
  • 在呼吸道感染(占所有感染的66.3%)分析中,支气管内受累(HR 4.27,95%CI 1.81至10.06)、严重支气管扩张(HR 6.14,95%CI 1.18至31.91)、较高中性粒细胞计数(HR 1.19,95%CI 1.06至1.33)和主要复发作为利妥昔单抗使用指征(HR 3.07,95%CI 1.30至7.23)与严重感染风险升高相关。
  • 难治性疾病作为利妥昔单抗使用指征与严重感染频率降低相关(HR 0.25,95%CI 0.07至0.90)。

关键数值与推荐

  • 严重感染按常见不良事件评价标准V.4.0定义为≥3级。
  • 复方磺胺甲噁唑预防与严重感染风险降低相关(HR 0.30,95%CI 0.13至0.69)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to assess risk factors for the development of severe infection in patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV) receiving rituximab. METHODS: 192 patients with AAV were identified. Univariate and multivariate analyses were performed to identify risk factors for severe infection following rituximab. Severe infections were classified as grade ≥3 as proposed by the Common Terminology Criteria for Adverse Events V.4.0. RESULTS: 95 severe infections were recorded in 49 (25.52%) patients, corresponding to an event rate of 26.06 per 100 person-years. The prophylactic use of trimethoprim-sulfamethoxazole was associated with a lower frequency of severe infections (HR 0.30, 95% CI 0.13 to 0.69), while older age (HR 1.03, 95% CI 1.01 to 1.05), endobronchial involvement (HR 2.21, 95% CI 1.14 to 4.26), presence of chronic obstructive pulmonary disease (HR 6.30, 95% CI 1.08 to 36.75) and previous alemtuzumab use (HR 3.97, 95% CI 1.50 to 10.54) increased the risk. When analysis was restricted to respiratory tract infections (66.3% of all infections), endobronchial involvement (HR 4.27, 95% CI 1.81 to 10.06), severe bronchiectasis (HR 6.14, 95% CI 1.18 to 31.91), higher neutrophil count (HR 1.19, 95% CI 1.06 to 1.33) and major relapse (HR 3.07, 95% CI 1.30 to 7.23) as indication for rituximab use conferred a higher risk, while refractory disease (HR 0.25, 95% CI 0.07 to 0.90) as indication had a lower frequency of severe infections. CONCLUSIONS: We found severe infections in one quarter of patients with AAV receiving rituximab. Trimethoprim-sulfamethoxazole prophylaxis reduced the risk, while especially bronchiectasis and endobronchial involvement are risk factors for severe respiratory infections.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kronbichler A, Kerschbaum J, Gopaluni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018. PMID: 29950327. doi:10.1136/annrheumdis-2017-212861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。